Cancer remains to be one of the dreaded diseases. However, with the advancement in research and medicine, there is a slow progress in finding the best antidote for this illness. According to new reports, scientists have discovered a potential treatment for lethal resistant prostate cancer.
What Is Prostate Cancer?
Cancer starts when cells in the body begin to grow uncontrollably. Any cell in your body has the potential to be cancer cells. In the case of prostate cancer, it begins when the cells in the prostate glands grow out of control. The prostate is only found in men, it contributes to some of the fluid that makes up the semen per Cancer.org.
According to statistics, there are about 180,890 new cases of prostate cancer in the United States in 2016. In addition, deaths due to this condition have already reached 26, 120.
New Study Found A Potential Treatment For Resistant Prostate Cancer
For men who are suffering from aggressive prostate cancer that no longer respond to conventional treatment, a new study has found a potential treatment for you. This new cancer drug is designed to overcome drug resistance, Science Daily reported.
Researchers found out that Hsp90 inhibitors, the new drug is capable of targeting and disengaging active prostate cancer cells by destabilizing multiple different proteins that are significant for the growth and survival of cancer cells, ICR reported.
This treatment destroys the cancer signals and makes it difficult for cancer cells to escape the effect of treatment. Hsp90 inhibition can also block the production of abnormal forms of androgen receptors, which makes cancer cells helpless against hormone treatment. This is a promising "resistance-busting" drug.
"We call Hsp90 inhibitors 'network drugs' because they tackle several of the signals that are hijacked in cancer all at once, across a network rather than just a single signalling pathway. These drugs can hit cancer harder than those targeting only one protein and look promising for preventing or overcoming drug resistance," said Professor Paul Workman, co-leader of the study.
"Our study has found that Hsp90 inhibition can specifically stop resistance to hormone treatments in prostate cancer, through a completely new mechanism of action involving the processing of messenger RNA," he added.
Professor Johann de Bono, stud co-leader revealed that the drugs are already in clinical trials for several types of cancer. He notes that this could potentially benefit prostate cancer patients who are suffering from resistant prostate cancers.
The study is published in the journal Cancer Research.
